New Zealand - English - Medsafe (Medicines Safety Authority)

sanofi-aventis new zealand limited - buserelin acetate 1.05 mg/ml equivalent to 1 mg/ml buscerelin - solution for injection - 1 mg/ml - active: buserelin acetate 1.05 mg/ml equivalent to 1 mg/ml buscerelin excipient: benzyl alcohol monobasic sodium phosphate dihydrate sodium chloride sodium hydroxide water for injection - for the treatment of endometriosis not primarily requiring surgical treatment. pituitary desensitisation in preparation for ovulation induction regimens using gonadotrophins.

New Zealand - English - Medsafe (Medicines Safety Authority)

pharmaco (nz) ltd - progesterone 100mg;  ; progesterone 100mg; progesterone 100mg; progesterone 100mg - capsule - 100 mg - active: progesterone 100mg   excipient: arachis oil gelatin glycerol soya oil titanium dioxide active: progesterone 100mg excipient: gelatin glycerol purified water soya oil sunflower oil titanium dioxide active: progesterone 100mg excipient: gelatin glycerol purified water soya oil sunflower oil titanium dioxide active: progesterone 100mg excipient: gelatin glycerol purified water soya oil sunflower oil titanium dioxide - adjunctive use with an oestrogen in postmenopausal women with an intact uterus (for hormone replacement therapy [hrt]).

Israel - English - Ministry of Health

unipharm ltd, israel - pravastatin sodium - tablets - pravastatin sodium 40 mg - pravastatin - pravastatin - pravastatin is indicated as a component of multiple risk factor intervention in those individuals at increased risk for atherosclerotic vascular disease due to hypercholesterolemia . pravastatin should be used in addition to a diet other nonpharmacological measures alone have been inadequate. primary prevention of coronary events: in hypercholesterolemic patients wihthout clinically evident coronary heart disease pravastatin is indicated to: 1) reduce the risk of myocardial infarcton. 2) reduce the risk for revascularization. 3) reduce the risk of deaths due to cardiovascular causes with no increase in death due to non-cardiovascular causes. secondary prevention of cardiovascular events: a) atherosclerosis: in hypercholesterolemic patients with clinically evident coronary artery disease including prior mi pravastatin is indicated to: 1)slow the progression of coronary atherosclerosis. 2) reduce the risk of acute coronary events. b) myocardial infarction: in patients with previ

Israel - English - Ministry of Health

bayer israel ltd - testosterone enantate - oily solution for injection - testosterone enantate 250 mg/ml - testosterone - testosterone - testosterone replacement therapy for male hypogonadism, when testosterone deficiency has been confirmed by clinical features and biochemical tests .puberty induction in boys with delayed puberty (pubertas tarda).

Israel - English - Ministry of Health

cts ltd - testosterone - gel - testosterone 0.05 mg/sachet - testosterone - testosterone - testosterone replacement therapy for male hypogonadism when testosterone deficiency has been confirmed by clinical features and biochemical tests.

Israel - English - Ministry of Health

bayer israel ltd - norethisterone acetate - tablets - norethisterone acetate 5 mg - norethisterone - norethisterone - oral progestron for: dysfunctional bleeding, primary and secondary amenorrhea, premenstrual syndrome, timing of mensturation and endometriosis.

Israel - English - Ministry of Health

sanofi - aventis israel ltd - buserelin acetate - rods for implant - buserelin acetate 9.9 mg - buserelin - buserelin - treatment of advanced hormone dependent prostatic carcinoma. however not after bilateral orchiectomy ( no further reduction of testosterone level by buserelin to be expected).

Ireland - English - HPRA (Health Products Regulatory Authority)

les laboratoires servier - estradiol hemihydrate - nasal spray solution - 150 micrograms/g

Ireland - English - HPRA (Health Products Regulatory Authority)

laboratoires besins international - testosterone - transdermal gel in sachet - 25 milligram(s) - 3-oxoandrosten (4) derivatives; testosterone

Ireland - English - HPRA (Health Products Regulatory Authority)

laboratoires besins international - testosterone - transdermal gel in sachet - 50 milligram(s) - 3-oxoandrosten (4) derivatives; testosterone